Actively Recruiting
Impact of Cardio-Selective Beta-Blockers on Infarct Size After Acute Myocardial Infarction
Led by Aristotle University Of Thessaloniki · Updated on 2025-12-19
100
Participants Needed
1
Research Sites
89 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Introduction: The effect of intravenous beta-blockers on the extent of the necrotic area, after primary percutaneous transluminal coronary angioplasty (PTCA), for acute myocardial infarction is not well established. Purpose: The present study aims to investigate, whether the early intravenous administration of landiolol, a highly cardioselective b-blocker, reduces the extent of the necrotic area after ST-elevation myocardial infarction (STEMI). Methods: This prospective observational cohort study will enroll patients presenting with STEMI, who undergo primary PCI and receive either intravenous landiolol or standard oral β-blocker therapy, in accordance with current European Society of Cardiology (ESC) guidelines. Eligibility will be determined by predefined inclusion and exclusion criteria. Treatment selection will be based solely on the clinical judgment of the attending cardiologist, without randomization. Results: Final infarct size will be quantified by cardiac magnetic resonance imaging (CMR) performed at least three months after the STEMI to minimize edema-related overestimation. Myocardial function will be assessed during hospitalization using transthoracic echocardiography, including measurement of global longitudinal strain (GLS). Additional data will include serial high-sensitivity troponin and creatine phosphokinase (CPK) measurements, 24-hour continuous electrocardiographic monitoring for arrhythmia burden, and predefined safety outcomes collected throughout hospitalization.
CONDITIONS
Official Title
Impact of Cardio-Selective Beta-Blockers on Infarct Size After Acute Myocardial Infarction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years
- Electrocardiogram showing ST-segment elevation 652 mm in 2 or more contiguous leads for more than 30 minutes
- Time from symptom onset to reperfusion less than or equal to 12 hours
- Scheduled to undergo primary angioplasty
- Signed a consent form
You will not qualify if you...
- Chronic use of beta-adrenergic blockers
- Previous myocardial infarction
- Persistent systolic blood pressure below 90 mmHg
- Persistent heart rate below 55 beats per minute
- Killip class III (acute pulmonary edema) or IV (cardiogenic shock) on initial exam
- PR interval greater than 200 milliseconds on ECG
- Second- or third-degree atrioventricular block on ECG
- Bronchospasm requiring bronchodilator treatment
- Possible pregnancy or postpartum period
- Unable or unwilling to sign consent form
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hippokration General Hospital of Thessaloniki
Thessaloniki, Thessaloniki, Greece, 546 42
Actively Recruiting
Research Team
A
Athina Nasoufidou, MD, MSc, PhDc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here